Stay updated on GSK2857916 Two Doses in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the GSK2857916 Two Doses in Multiple Myeloma Clinical Trial page.

Latest updates to the GSK2857916 Two Doses in Multiple Myeloma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content changes regarding the study of belantamab mafodotin for multiple myeloma, including the removal of detailed participant criteria and study protocols, while retaining the EudraCT number and revision information.SummaryDifference14%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.4%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.4%
Stay in the know with updates to GSK2857916 Two Doses in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GSK2857916 Two Doses in Multiple Myeloma Clinical Trial page.